BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27860149)

  • 1. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
    Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
    BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal medullary carcinoma: A national analysis of 159 patients.
    Ezekian B; Englum B; Gilmore BF; Nag UP; Kim J; Leraas HJ; Routh JC; Rice HE; Tracy ET
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28485059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
    J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
    Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
    Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
    Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
    Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
    Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal medullary carcinoma and its association with sickle cell trait: a case report and literature review.
    Holland P; Merrimen J; Pringle C; Wood LA
    Curr Oncol; 2020 Feb; 27(1):e53-e56. PubMed ID: 32218668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
    Carter SA; Walker AN
    J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
    Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
    BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Medullary Carcinoma: a Report of the Current Literature.
    Blas L; Roberti J; Petroni J; Reniero L; Cicora F
    Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
    Sodji Q; Klein K; Sravan K; Parikh J
    J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
    Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
    Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
    J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.
    Psutka SP; Heidenreich M; Boorjian SA; Bailey GC; Cheville JC; Stewart-Merrill SB; Lohse CM; Atwell TD; Costello BA; Leibovich BC; Thompson RH
    BJU Int; 2017 Jan; 119(1):116-127. PubMed ID: 27489013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.